Literature DB >> 2249334

VIM-D salvage chemotherapy in Hodgkin's disease.

J K Phillips1, R L Spearing, J M Davies, C R Hay, H Parry, J R Nash, J C Cawley.   

Abstract

A total of 15 patients with relapsed or resistant Hodgkin's disease were treated with a combination of etoposide (VP16), ifosfamide, mitozantrone and dexamethasone (VIM-D). The regime was well tolerated, the only major toxicity being myelosuppression. Complete remissions (CRs) were obtained in 4 patients and were maintained for 2, 4, 10 and 14 months. 10 subjects subsequently received an autologous bone marrow transplant with high-dose chemotherapy (ABMT). Previous exposure to VIM-D did not appear to predict for or prejudice the response to subsequent ABMT.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2249334     DOI： 10.1007/bf00689103

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  6 in total

1.  Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.

Authors:  C A Coltman; T M McDaniel; S P Balcerzak; F S Morrison; D D Von Hoff
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

2.  A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

Authors:  M L Slevin; P I Clark; S P Joel; S Malik; R J Osborne; W M Gregory; D G Lowe; R H Reznek; P F Wrigley
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

3.  High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.

Authors:  S Jagannath; K A Dicke; J O Armitage; F F Cabanillas; L J Horwitz; L Vellekoop; A R Zander; G Spitzer
Journal:  Ann Intern Med       Date:  1986-02       Impact factor: 25.391

4.  MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease.

Authors:  P Klimo; J M Connors
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

5.  A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease.

Authors:  M R Cooper; T F Pajak; N I Nissen; L Stutzman; K Brunner; J Cuttner; G Falkson; H Grunwald; A Bank; L Leone; B R Seligman; R T Silver; R B Weiss; F Haurani; J Blom; C L Spurr; O J Glidewell; A J Gottlieb; J F Holland
Journal:  Cancer       Date:  1980-08-15       Impact factor: 6.860

6.  Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.

Authors:  P J Dady; T J McElwain; D E Austin; A Barrett; M J Peckham
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640
  6 in total
  2 in total

1.  Hodgkin lymphoma, version 2.2015.

Authors:  Richard T Hoppe; Ranjana H Advani; Weiyun Z Ai; Richard F Ambinder; Patricia Aoun; Celeste M Bello; Cecil M Benitez; Philip J Bierman; Kristie A Blum; Robert Chen; Bouthaina Dabaja; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Ephraim P Hochberg; Jiayi Huang; Patrick B Johnston; Nadia Khan; David G Maloney; Peter M Mauch; Monika Metzger; Joseph O Moore; David Morgan; Craig H Moskowitz; Carolyn Mulroney; Matthew Poppe; Rachel Rabinovitch; Stuart Seropian; Christina Tsien; Jane N Winter; Joachim Yahalom; Jennifer L Burns; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2015-05       Impact factor: 11.908

2.  Chemotherapy followed by low dose radiotherapy in childhood Hodgkin's disease: retrospective analysis of results and prognostic factors.

Authors:  Gustavo A Viani; Marcus S Castilho; Paulo E Novaes; Celia G Antonelli; Robson Ferrigno; Cassio A Pellizzon; Ricardo C Fogaroli; Maria A Conte; Joao V Salvajoli
Journal:  Radiat Oncol       Date:  2006-10-02       Impact factor: 3.481
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.